Triple-Drug cocktail shows promise for tough lung cancers
NCT ID NCT04791839
First seen Nov 05, 2025 · Last updated Jun 14, 2026 · Updated 31 times
Summary
This study tests a combination of three drugs (zimberelimab, domvanalimab, and etrumadenant) in 30 adults with advanced non-small cell lung cancer who have already tried immunotherapy. The goal is to see if the triple therapy can shrink tumors and how safe it is. Participants must have a certain level of PD-L1 protein on their tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.